Medtronic plc announced that the Journal of Thoracic Oncology has published 12-month results of the NAVIGATE study, the largest, prospective, multicenter trial evaluating electromagnetic navigation bronchoscopy (ENB) procedures using the superDimension navigation system to aid in lung cancer diagnosis, staging and treatment. NAVIGATE included a key finding that 65% of patients diagnosed by physicians with primary lung cancer were at early stages (Stage I or II) of the disease. Early detection of lung cancer is critical to improving patient outcomes long term. According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in the United States.(1) Today, the majority of lung cancer patients are diagnosed in the late stages (Stage III or IV), during which long-term survival rates drastically decline.(1) When diagnosed at Stage I, the estimated 10-year survival rate climbs to 88%.(2) Early detection and immediate treatment dramatically increases the typical long-term survival rate. Advancing the Lung Cancer Care Continuum Through Real-World Diagnostic Data ENB procedures provide a minimally invasive, GPS-like approach to accessdifficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and potentially lead to earlier, personalized treatment. Earlier treatment has been associated with improved survival. NAVIGATE enrolled subjects at 37 sites in the United States and Europe. The Journal of Thoracic Oncology publication presents 12 month follow up for 1,215 patients at 29 medical centers in the United States. The NAVIGATE study results showed the diagnostic yield of ENB (the proportion of patients who obtain an ENB-aided diagnosis) as supported by one-year follow-up. The ENB procedure was successfully completed in 94% of study patients and an ENB-aided diagnosis was obtained in 73%.(3) Compared to published diagnostic yields of 65-73% in previous small, single-center, and retrospective studies across different devices,(4,5) the one-year diagnostic yield in NAVIGATE is consistent and generalizable across diverse operators. A key finding in the NAVIGATE data was that 65% of patients diagnosed by physicians with primary lung cancer were at early stages of the disease (Stage I-II). With 49% of lesions less than 20 mm in diameter, NAVIGATE confirmsthat ENB is suitable for evaluating small peripheral lesions. The procedure had lower complication rates than previously published for transthoracic needle biopsies; specifically, pneumothorax (collapsed lung caused by injury to thelung wall) occurred in only 4.3% of NAVIGATE patients, which is lower than 19-25% rates typically seen with transthoracic needle biopsies. Building on the NAVIGATE results, Medtronic continues to advance lung cancer diagnostics. The latest generation of ENB, the superDimension(TM) Navigation System Version 7.2 with Fluoroscopic Navigation Technology, uses advanced software to enhance the visibility of lung lesions in real-time and aid in improved diagnostic accuracy. Medtronic has recently launched a new prospective study evaluating this technology at two United States centers. Expanding the Care Continuum Through the New NAVABLATE Clinical Study Medtronic is also committed to optimizing minimally invasive treatment solutions that accelerate recovery. A third study, NAVABLATE, will characterize the safety and performance of bronchoscopic thermal ablation using the Emprint(TM) ablation catheter kit with Thermosphere(TM) technology guided by the superDimension navigation system. The prospective, multi-center NAVABLATE study will be conducted in up to 30 patients globally.